Mammary Cell News Volume 8.41 | Oct 20 2016

TOP STORY

Snail1-Dependent p53 Repression Regulates Expansion and Activity of Tumor-Initiating Cells in Breast Cancer

Using a Snail1 conditional knockout model of mouse breast cancer that maintains wild-type p53, the authors found that Snail1 plays an essential role in tumor progression by controlling the expansion and activity of tumor-initiating cells in preneoplastic glands and established tumors, whereas it is not required for normal mammary development. [Nat Cell Biol] Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

Long-Term Exposure to Bisphenol A or Benzo(a)Pyrene Alters the Fate of Human Mammary Epithelial Stem Cells in Response to BMP2 and BMP4, by Pre-Activating BMP Signaling

Researchers demonstrated that chronic exposure to low doses of bisphenol A or benzo(a)pyrene alone has little effect on stem cells properties of MCF10A cells. [Cell Death Differ] Full Article

Genomic Modeling of the ESR1 Y537S Mutation for Evaluating Function and New Therapeutic Approaches for Metastatic Breast Cancer

The authors used CRISPR-Cas9 genome editing to make a single allele knock-in of the most commonly mutated amino acid residue, tyrosine 537, in the estrogen-responsive MCF7 breast cancer cell line. [Oncogene] Full Article

Acquired CDK6 Amplification Promotes Breast Cancer Resistance to CDK4/6 Inhibitors and Loss of ER Signaling and Dependence

Scientists investigated mechanisms of acquired resistance to CDK4/6 inhibition. They established cell lines that were chronically exposed to the CDK4/6 inhibitor and identified amplification of CDK6 as a recurrent event. [Oncogene] Full Article

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-Pyrazolo[3,4-D]Pyrimidin-4-Amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer

Investigators reported the process of structural optimization towards a previously disclosed Src inhibitor, compound 1, which showed high potency in the treatment of triple negative breast cancer both in vitro and in vivo, but had considerable toxicity. [J Med Chem] Abstract

Microfluidic Co-Culture System for Cancer Migratory Analysis and Anti-Metastatic Drugs Screening

Researchers presented a novel microfluidic co-culture system and established mild, moderate and severe cancer models by using HMEpiC and MDA-MB–231 cells to study cancer cell migration and anti-cancer drug screening. [Sci Rep] Full Article

CDK4 Regulates Cancer Stemness and Is a Novel Therapeutic Target for Triple-Negative Breast Cancer

Scientists found the cyclin-dependent kinase (CDK4) to act as a cancer stem cell regulator and novel prognostic marker in triple negative breast cancers. [Sci Rep] Full Article

Radiosensitizing Effect of Lapatinib in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cells

To explore the impact of lapatinib on radiation response, the authors conducted an in vitro experiment using SKBR3 and BT474 breast carcinoma cells exhibiting human epidermal growth factor receptor 2/neu amplification. [Oncotarget] Full Article

Targeting Aberrant Expression of Notch-1 in ALDH⁺ Cancer Stem Cells in Breast Cancer

Researchers examined the functional and clinical significance of aldehyde dehydrogenase (ALDH) expression by measuring the ALDH levels in breast cancer tissues by immunohistochemistry. [Mol Carcinog] Abstract

CLINICAL RESEARCH

A Randomized Phase II Study of Veliparib with Temozolomide or Carboplatin/Paclitaxel versus Placebo with Carboplatin/Paclitaxel in BRCA1/2 Metastatic Breast Cancer: Design and Rationale

Scientists investigated whether the addition of veliparib to temozolomide or carboplatin/paclitaxel provides clinical benefit over carboplatin/paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer harboring a deleterious BRCA1 or BRCA2 germline mutation. [Future Oncol] Full Article

Palmitoylation: A Protein S-Acylation with Implications for Breast Cancer

The authors summarize emerging evidence and highlight knowledge gaps for a role for aberrant palmitoylation in breast cancer. [NPJ Breast Cancer] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Atrin Pharmaceuticals Awarded $300,000 Phase I Contract for Development of Highly Specific ATR Inhibitors for Targeted Cancer Treatment

Atrin Pharmaceuticals, Inc. announced receipt of a Phase I Small Business Technology Transfer Award for approximately $300,000 from the National Cancer Institute of the National Institutes of Health. The award supports Atrin’s development of highly specific inhibitors of ATR for the targeted treatment of a broad spectrum of cancers. [Atrin Pharmaceuticals, Inc. (PR Newswire Association LLC)] Press Release

Mount Sinai Receives $10 Million Grant to Study Graft vs. Host Disease

Researchers from the Icahn School of Medicine at Mount Sinai have been awarded a $10 million from the National Cancer Institute to explore the cellular and molecular mechanisms of acute graft-versus-host disease, a common side effect that occurs after allogeneic bone marrow transplantation (BMT), and to develop novel therapeutic strategies for BMT patients with cancer that begin in the cells of blood-forming tissue or hematologic malignancies. [Mount Sinai Health System] Press Release

Reports of ‘Three-Parent Babies’ Multiply

Claims of infants created using mitochondrial-replacement techniques stir scientific and ethical debate. [Nature News] Editorial

How Republicans Reshaped the House Science Committee

Lamar Smith has made his mark on science. As chairman of the US House Committee on Science, Space, and Technology, the Texas Republican has launched dozens of investigations into alleged wrongdoing by scientists, environmental groups and government officials. And he shows no signs of slowing down. [Nature News] Editorial

U.S. and Cuban Biomedical Researchers Are Free to Collaborate

The U.S. Department of the Treasury has authorized U.S. scientists to freely collaborate with Cuban counterparts on everything from cancer therapies to combatting the Zika virus. [Science Insider] Editorial

Biden’s Moonshot Cancer Plan Calls for More Data Sharing

Vice President Joe Biden released his vision for doubling progress against cancer over 5 years. It includes numerous policy recommendations and a laundry list of projects by the National Cancer Institute and other federal agencies that would require additional funding. [Science Insider] Editorial

NEW 29^th Lorne Cancer Conference
February 9-11, 2017
Lorne, Australia

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Training Fellow (Institute of Cancer Research)

Research Associate – Patient-Derived Organoid Models of Breast Cancer (King’s College London)

Postdoctoral Fellow – BioMarker Research Cancer (Houston Methodist Research Institute)

Post Doctoral Associate – Mammary Stem Cell and Cancer Biology (University of Miami)

Post Doctoral Position – Neovascularization and Cancer Biology (The Ohio State University)

Postdoctoral Associate – Functional Genomics and Cancer (The Jackson Laboratory)

Assistant Professor – Physiology and Biophysics (University of Illinois at Chicago)

Postdoctoral Position or Internship – Cancer Research (Stanford University)

Postdoctoral Researcher – Breast Cancer (Purdue University)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.